News & media

Featured story
June 5, 2025

Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease

Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases CAMBRIDGE, Mass., June 5, 2025 — Casma Therapeutics, Inc., a biotechnology company engaging the autophagy and lysosomal systems to develop innovative new medicines, today announced the nomination of its first development candidate, CSM-101, a first-in-class TRPML1 agonist. […]

June 5, 2025
Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease

Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases CAMBRIDGE, Mass., June 5, 2025 — Casma Therapeutics, Inc., a biotechnology company engaging the autophagy and lysosomal systems to develop innovative new medicines, today announced the nomination of its first development candidate, CSM-101, a first-in-class TRPML1 agonist. […]

April 17, 2024
Casma Therapeutics to Participate at 23rd Annual Needham Virtual Healthcare Conference and at UBS Virtual Targeted Protein Degradation Day

CAMBRIDGE, Mass., April 17, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Frank Gentile, PhD, Chief Executive Officer, presented and participated in one-on-one meetings at the 23rd Annual Needham Virtual Healthcare Conference on April 5, 2024. Frank Gentile, PhD, will also attend and participate in […]

February 28, 2024
Casma Therapeutics to Present at the Gordon Research Conference on Autophagy in Stress, Development, and Disease

CAMBRIDGE, Mass., February 28, 2024– Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Leon Murphy, Ph.D., Chief Scientific Officer and Dan Baird Ph.D., Vice President, Molecular Discovery will participate in the Gordon Research Conference on Autophagy in Stress, Development, and Disease in Lucca, Italy. Dr. […]

February 13, 2024
Casma Therapeutics to Present at the Keystone Symposia on Tumor Metabolism

CAMBRIDGE, Mass., February 12, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Leon Murphy, Ph.D., Chief Scientific Officer, will present at the Keystone Meeting on Tumor Metabolism in Banff, Alberta, Canada, in the “Targeting Metabolism” Section. The title of Dr. Murphy’s talk is […]

January 22, 2024
Casma Therapeutics to Present at the Joint Keystone Meeting for Proximity Based Therapeutics and Targeted Protein Degradation

CAMBRIDGE, Mass., January 22, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Leon Murphy, Ph.D., Chief Scientific Officer, will present at the joint Keystone Meeting for Proximity Based Therapeutics and Targeted Protein Degradation in the section of “Emerging Proximity Biology for Target Degradation.”  […]

January 31, 2023
Casma Therapeutics Announces CEO Transition

  CAMBRIDGE, Mass., January 31, 2023 – Casma Therapeutics, a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., has stepped down as Chief Executive Officer, effective January 13, 2023. Dr. Dionne will continue to serve on the Board of Directors. Frank Gentile, Ph.D., formerly Chief Operating Officer […]

January 30, 2023
Casma Therapeutics Announces new Nature Publication – “Structure of the lysosomal mTORC1–TFEB–Rag–Ragulator megacomplex”

In their recent Nature paper, Casma Founders Jim Hurley and Andrea Ballabio describe the cryogenic-EM structure of an MTORC1 megacomplex.  A molecular description of this massive complex is helping us understand the regulation of the TFEB transcription factor and dependence of TFEB phosphorylation on FLCN and the RagC GDP state. Read full publication here

November 15, 2022
Casma Therapeutics Raises $46.0 M in Series C Funding

CAMBRIDGE, Mass., November 15, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono […]

November 8, 2022
Casma Therapeutics to Present at Stifel 2022 Healthcare Conference

CAMBRIDGE, Mass., November 8, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the Stifel 2022 Healthcare Conference on Wednesday November 16,, 2022 at 3:00pm ET in New York, NY. About Casma Therapeutics, Inc. Casma […]

May 17, 2022
Casma Therapeutics to Present at UBS 2022 Global Healthcare Conference

CAMBRIDGE, Mass., May 17, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the UBS 2022 Global Healthcare Conference on Tuesday, May 24, 2022 at 11:30 a.m. ET in New York, NY. About Casma Therapeutics […]

Page 1 of 4